May 6th 2025
The bispecific T-cell engager tarlatamab demonstrated favorable antitumor activity in a small cohort with small cell lung cancer (SCLC), but it was also linked to higher rates of serious adverse events like cytokine release syndrome than seen in clinical trials.
Watch the series now!
Age Is Not a Risk Factor for Post-Mastectomy Reconstructive Surgery
Employers Express Their Concerns With Cancer Care at the COA Summit
How Can Practices Seek Success With Oncology Payment Reform?
Dr Marianne Fazen on Why Cancer Is a Major Concern for Employers